Steering the course of CAR T cell therapy with lipid nanoparticles.
J Nanobiotechnology
; 22(1): 380, 2024 Jun 28.
Article
em En
| MEDLINE
| ID: mdl-38943167
ABSTRACT
Lipid nanoparticles (LNPs) have proven themselves as transformative actors in chimeric antigen receptor (CAR) T cell therapy, surpassing traditional methods and addressing challenges like immunogenicity, reduced toxicity, and improved safety. Promising preclinical results signal a shift toward safer and more effective CAR T cell treatments. Ongoing research aims to validate these findings in clinical trials, marking a new era guided by LNPs utility in CAR therapy. Herein, we explore the preference for LNPs over traditional methods, highlighting the versatility of LNPs and their effective delivery of nucleic acids. Additionally, we address key challenges in clinical considerations, heralding a new era in CAR T cell therapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Imunoterapia Adotiva
/
Nanopartículas
/
Receptores de Antígenos Quiméricos
/
Lipídeos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article